
The START Center for Cancer Research (“START”) is the world’s largest early phase site network, fully dedicated to oncology clinical research. To date, over 45 therapies conducted at START locations have obtained FDA/EMA approval.
The START Center for Cancer Research is seeking a Clinical Research Coordinator, RN. The Clinical Research Coordinator, RN will work under the guidance of senior research staff to support the daily activities of early phase oncology clinical trials. The CRC, RN ensures the accurate and timely conduct of clinical research, adhering to protocols, regulatory requirements, and patient safety standards. This role involves direct patient interaction, data collection, and maintaining compliance with Good Clinical Practice (GCP). The Clinical Research Coordinator will be assigned multiple protocols at any time for which they will oversee the aspects of assigned protocols with planning and coordinating patient participation in the trial. Also, this role is responsible for implementation as well as completion of protocol specific requirements, providing accurate, up to date information to all team members involved with any aspect of carrying out protocol specific requirements.
The hourly pay rate for this role is $45/hour-$65/hour. However, base pay may vary depending on multiple individualized factors including market location, job-related knowledge, skills, and experience.
Work Schedule: Monday-Friday 8:00am-5:00pm
Location: START Midwest - 5800 Foremost Dr SE Grand Rapids, Michigan 49546
Essential Responsibilities
Required Education and Experience:
Preferred Education and Experience:
Physical & Travel Requirements:
Best-in-Class Benefits and Perks
We value our employees’ time and efforts. Our commitment to your success is enhanced by a competitive compensation, depending on experience, and an extensive benefits package including:
More about The START Center for Cancer Research
Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a thousand early-phase clinical trials, including for 43 therapies that were approved by the FDA. START represents the world’s largest roster of Principal Investigators (PIs) across its eight clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world.
Learn more at STARTresearch.com.
Ready to be part of a team changing the future of cancer treatment?
Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.
We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.

Deeply rooted in community oncology centers globally, the START Center for Cancer Research ("START") provides patients with access to specialized Phase 1 clinical trials for novel anti-cancer agents. With research sites in the United States and in Spain, Portugal, and Ireland, START’s clinical trial sites have conducted more than 1,500 early phase clinical trials, including for 45 therapies that have gained FDA/EMA approval. Founded in Texas in 2007, START today boasts 30+ Principal Investigators (PIs) across its worldwide clinical trial sites. With over 100,000+ square feet of world-class research facilities, START offers patients comprehensive treatment plans that include multi-specialty services, genetic profiling of tumors, targeted therapies, state-of-the-art treatment technology, and advanced access to clinical research options. START is committed to accelerating passage from trials to treatments, and to delivering hope to patients, families, and physicians around the world.